Overview

A Study of TG103 Injection in Type 2 Diabetes Subjects

Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.